Latest News for: t-cell lymphomas

Edit

B-Cell Lymphomas Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, ...

GetNews 28 Mar 2025
(Albany, USA) DelveInsight's "B-Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of B-Cell Lymphomas, historical and forecasted ...
Edit

Peripheral T-cell Lymphoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, ...

GetNews 28 Mar 2025
Peripheral T-cell Lymphoma Epidemiology Segmentation in the 7MM Total Peripheral T-cell Lymphoma Incident Cases Peripheral T-cell Lymphoma Stage-Specific Incident Cases (Stage I, Stage II, Stage III, ...
Edit

Cutaneous T-Cell Lymphoma (CTCL) Treatment Market 2034: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, ...

GetNews 28 Mar 2025
(Albany, USA) DelveInsight's "Cutaneous T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Cutaneous T-Cell Lymphoma, historical and ...
Edit

CM’s Fund helps city youth overcome cancer

The Times of India 28 Mar 2025
Tirthankar Niranjan Roy, a 26-year-old IT engineer from Nagpur, successfully recovered from Stage 4 Hodgkin's lymphoma after undergoing an autologous stem cell transplant at Tata Memorial Hospital, Mumbai.
Edit

Experts discover people with tattoos have DOUBLE the risk of deadly cancers - the larger ...

The Daily Mail 27 Mar 2025
But for those with body art larger than the palm of a hand, the risk of skin cancer increased by 137 per cent and for lymphoma, a type of blood cancer, the risk soared to 173 per cent ... About 17,000 cases of lymphoma are diagnosed in the UK each year.
Edit

Ryvu Therapeutics Announces Dosing of the First Patient in the JASPIS-01 Phase II Study of Dapolsertib (MEN1703/SEL24) for the Treatment of r/r DLBCL

Pharmiweb 27 Mar 2025
... dosed in the JASPIS-01 study, a Phase II clinical trial investigating dapolsertib (MEN1703, SEL24) for the treatment of patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Edit

Photo Gallery: Colton Strong community blood and toy drive at Central Catholic

Toledo Blade 26 Mar 2025
... been fighting T-cell Lymphoblastic Lymphoma since July 2023.
Edit

Acute Lymphocytic Leukemia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ...

GetNews 26 Mar 2025
... chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.
Edit

Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 25 Mar 2025
... Non-hodgkin's Lymphoma ... Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma.
Edit

Two Boys Cancer — One Town’s Help

Weekly Villager 25 Mar 2025
Ribbon ... Preliminary diagnosis was Lymphoma, due to a large mass in his hip. The lad then underwent 27 biopsy procedures leading to the diagnosis B-Cell Leukemia ... Paddy’s Day ... He has since been diagnosed with T-Cell Lymphoma/Blastic Leukemia ... .
Edit

Diffuse Large B-cell Lymphoma Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Insights Unveiled ...

GetNews 25 Mar 2025
Diffuse Large B-cell Lymphoma current marketed and Diffuse Large B-cell Lymphoma emerging therapies ... Diffuse Large B-cell Lymphoma market drivers and Diffuse Large B-cell Lymphoma market barriers.
Edit

Cancer in remission, Carroll College's Niles seeks comeback

Independent Record 25 Mar 2025
HELENA — Cam Niles spent the early days of an Anaplastic Large Cell Lymphoma diagnosis seeking and failing to answer a question all 21-year-old cancer patients likely ask. Why? ... .
Edit

New Microscopy Technique Challenges Therapeutic Antibody Classification

The Scientist 25 Mar 2025
They started by treating human lymphoma cells with one of four different mAbs, classified as type I or II based on how they interact with CD20 and induce cell-death ... Cell & Molecular Biology. Illuminating Specimens Through Live Cell Imaging.
Edit

B-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 24 Mar 2025
... B-Cell Lymphoma- Unmet Needs B-Cell Lymphoma- Market Drivers and Barriers B-Cell Lymphoma- Future Perspectives and Conclusion B-Cell Lymphoma Analyst Views B-Cell Lymphoma Key Companies Appendix.
Edit

CAR-T Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, ...

GetNews 24 Mar 2025
The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed').

Article Search

tools
×
×
×
×